Regeneron's blockbuster eye drug posts weaker sales due to inventory impact
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
Regeneron Pharma (REGN) PT Lowered to $1,185 at RBC Capital
May 3, 2024 6:46 AM EDTRBC Capital analyst Brian Abrahams lowered the price target on Regeneron Pharma (NASDAQ: REGN) to $1,185.00 (from $1,189.00) while maintaining a Outperform rating.
The analyst comments "Overall, a reasonably solid quarter, with Eylea HD looking good, Eylea 2mg missing probably to a... More
Regeneron (REGN) misses earnings, revenue expectations
May 2, 2024 7:05 AM EDTRegeneron (NASDAQ: REGN) experienced a slight decline in its stock price, falling 1.82% after reporting first-quarter earnings and revenue that fell short of Wall Street expectations. The biotechnology company announced an adjusted EPS of $9.55, which was below the analyst estimate of $10.19. Revenue for the quarter was $3.15 billion, also missing the consensus estimate of $3.22 billion.
Despite the overall revenue decrease of 1% from the same quarter last year, the company highlighted a 7% increase when excluding sales from Ronapreve, a COVID-19 treatment. Notably,... More
